Marc Machaalani (@marcmachaalani) 's Twitter Profile
Marc Machaalani

@marcmachaalani

Postdoctoral Research Fellow @DanaFarber | MD '23 @LebaneseUni | Classical Pianist

ID: 1917419509

calendar_today29-09-2013 15:20:41

1,1K Tweet

679 Followers

676 Following

Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

KIM-1 is leading the biomarker strategies in #KidneyCancer ! Our very own brilliant research fellow Marc Machaalani from Dana-Farber Lank Center for Genitourinary Oncology is presenting the molecular analyses results of KIM-1! #ASCO25 Happy to be a part of this great work! Toni Choueiri, MD ASCO Renee Maria Saliby

KIM-1 is leading the biomarker strategies in #KidneyCancer ! Our very own brilliant research fellow <a href="/MarcMachaalani/">Marc Machaalani</a> from <a href="/DanaFarber_GU/">Dana-Farber Lank Center for Genitourinary Oncology</a> is presenting the molecular analyses results of KIM-1! #ASCO25 

Happy to be a part of this great work!

<a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/ASCO/">ASCO</a> <a href="/ReneeSaliby/">Renee Maria Saliby</a>
Rafeh Naqash, MD (@thenasheffect) 's Twitter Profile Photo

Immune Checkpoint Inhibitors for Patients With Autoimmune Neurologic Disorders. Fantastic realworld collaboration on a clinically relevant Q, JAMA Network Open jamanetwork.com/journals/jaman…

Immune Checkpoint Inhibitors for Patients With Autoimmune Neurologic Disorders.  Fantastic realworld collaboration on a clinically relevant Q, <a href="/JAMANetworkOpen/">JAMA Network Open</a> 

jamanetwork.com/journals/jaman…
Emre Yekedüz (@yekeduz_emre) 's Twitter Profile Photo

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

🚨 Our new study alert! <a href="/ElsevierConnect/">Elsevier</a> 

What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma?

🎯Endpoints : Overall surival and time to treatment failure

High comorbidity 🟰 Worse Outcomes

❓❗️No
Arya Roy (@royaryam) 's Twitter Profile Photo

🚨Proud to share our publication in JCO Oncology Practice 🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! Toni Choueiri, MD Nazli Dizman Ziad Bakouny, MD, MSc IMG Oncologists gilberto lopes

🚨Proud to share our publication in <a href="/JCOOP_ASCO/">JCO Oncology Practice</a> 
🧵International Medical Graduates (IMGs) are underrepresented in invited faculty roles at #ASCO Annual Meetings, despite their contributions to original research! <a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/NazliDizman/">Nazli Dizman</a> <a href="/ZiadBakouny/">Ziad Bakouny, MD, MSc</a> <a href="/IMG_Oncologists/">IMG Oncologists</a> <a href="/GlopesMd/">gilberto lopes</a>
Marc Machaalani (@marcmachaalani) 's Twitter Profile Photo

Enjoyed working with Clara Steiner on this review of KIM-1 as a biomarker in RCC. Given the compelling retrospective data, prospective validation is the clear next step. Wenxin (Vincent) Xu Eur Urol Focus

KidneyCAN (@kidneycan) 's Twitter Profile Photo

#KCRS25 Oral Abstract: Marc Machaalani, MD Dana-Farber highlights KIM-1 as a potential blood biomarker to predict RCC treatment response and prognosis. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25 #AcceleratingCures

#KCRS25 Oral Abstract: <a href="/MarcMachaalani/">Marc Machaalani, MD</a> <a href="/DanaFarber/">Dana-Farber</a> highlights KIM-1 as a potential blood biomarker to predict RCC treatment response and prognosis.

Read all the abstracts: bit.ly/AbstractsKCRS25
Register: bit.ly/RegisterKCRS25

#AcceleratingCures
koral shah, md (@kor_shah) 's Twitter Profile Photo

Exciting talk by David Braun at #KCRS2025 on not only the feasibility of personalized neoantigen vaccines in #kidneycancer , but also preclinical evidence of T cell response & preliminary promising clinical activity 💉🧬 KidneyCAN UroToday.com OncoAlert

Exciting talk by <a href="/BraunMDPhD/">David Braun</a> at #KCRS2025 on not only the feasibility of personalized neoantigen vaccines in #kidneycancer , but also preclinical evidence of T cell response &amp; preliminary promising clinical activity 💉🧬
<a href="/kidneycan/">KidneyCAN</a> <a href="/urotoday/">UroToday.com</a> <a href="/OncoAlert/">OncoAlert</a>
Renee Maria Saliby (@reneesaliby) 's Twitter Profile Photo

Microbiome expert Carolina Alves Costa Silva, MD, PhD elegantly presentsthe data on MAdCAM-1 in association with outcomes to IO-based therapies Circulating MadCAM-1 is a promising baseline and dynamic biomarker I love our 💩team! Marc Machaalani, MD #KCRS25 OncoAlert

Microbiome expert <a href="/CarolinaAlvesC5/">Carolina Alves Costa Silva, MD, PhD</a> elegantly presentsthe data on MAdCAM-1 in association with outcomes to IO-based therapies

Circulating MadCAM-1 is a promising baseline and dynamic biomarker

I love our 💩team! <a href="/MarcMachaalani/">Marc Machaalani, MD</a> 

#KCRS25 <a href="/OncoAlert/">OncoAlert</a>
Renee Maria Saliby (@reneesaliby) 's Twitter Profile Photo

Takeaways from Wenxin (Vincent) Xu 's majestic talk on biomarkers: - Several biomarkers have been studied in RCC - Current biomarkers in RCC do not correspond to patient's goals - The future is in integrative biomarkers - Let's get back to work to answer all the different questions

Takeaways from <a href="/VincentWenxinXu/">Wenxin (Vincent) Xu</a> 's majestic talk on biomarkers:
- Several biomarkers have been studied in RCC
- Current biomarkers in RCC do not correspond to patient's goals
- The future is in integrative biomarkers
- Let's get back to work to answer all the different questions
Zeynep Irem Ozay, MD (@ziremozay) 's Twitter Profile Photo

🌟Happening now at #KCRS25👉 Marc Machaalani, MD presenting an integrative clinical, genomic, transcriptomic and immunopathologic analysis of circulating KIM-1 in metastatic RCC #kidneycancer👇 KidneyCAN OncoAlert UroToday.com

🌟Happening now at #KCRS25👉 <a href="/MarcMachaalani/">Marc Machaalani, MD</a> presenting an integrative clinical, genomic, transcriptomic and immunopathologic analysis of circulating KIM-1 in metastatic RCC #kidneycancer👇

<a href="/kidneycan/">KidneyCAN</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/urotoday/">UroToday.com</a>
Mustafa Saleh (@mustafajsalehmd) 's Twitter Profile Photo

Rocking the stage Marc Machaalani, MD with his work on KIM-1 levels in JAVELINE 101 trial: 1. Patients with higher levels of KIM1 at baseline worse OS, PFS. 2. KIM 1 levels associated with BAP1 and proliferative signature. 3. KIM1 + IMDC + change in KIM1 achieved an AUC of 0.76

Rocking the stage <a href="/MarcMachaalani/">Marc Machaalani, MD</a> with his work on KIM-1 levels in JAVELINE 101 trial: 
1. Patients with higher levels of KIM1 at baseline worse OS, PFS. 
2. KIM 1 levels associated with BAP1 and proliferative signature.
3. KIM1 + IMDC + change in KIM1 achieved an AUC of 0.76
Renee Maria Saliby (@reneesaliby) 's Twitter Profile Photo

🚨Internal medicine applicant Marc Machaalani, MD presents the work on KIM-1 like a pro⭐️ KIM-1 is a promising biomarker as well as a great reflection of broader tumor biology #KCRS25 OncoAlert

🚨Internal medicine applicant <a href="/MarcMachaalani/">Marc Machaalani, MD</a> presents the work on KIM-1 like a pro⭐️

KIM-1 is a promising biomarker as well as a great reflection of broader tumor biology

#KCRS25 <a href="/OncoAlert/">OncoAlert</a>
Clara Steiner (@clara__steiner) 's Twitter Profile Photo

A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague Marc Machaalani, MD — another key step in the evolving story of KIM-1 in RCC with more to come!! Wenxin (Vincent) Xu Toni Choueiri, MD

A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague <a href="/MarcMachaalani/">Marc Machaalani, MD</a> — another key step in the evolving story of KIM-1 in RCC with more to come!! 

<a href="/VincentWenxinXu/">Wenxin (Vincent) Xu</a> <a href="/DrChoueiri/">Toni Choueiri, MD</a>